<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the effect of regional cerebral blood flow on the effect of midazolam, we evaluated 99mTc-hexamethylpropylene-<z:chebi fb="39" ids="32952">amine</z:chebi>-<z:chebi fb="0" ids="25750">oxime</z:chebi>-single <z:chebi fb="23" ids="30212">photon</z:chebi> emission computed tomography (SPECT) in 37 cases of childhood <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>They were divided into two groups according to the findings of SPECT; one group showed hypoperfusion in the bifrontal regions (n = 20), and the other did not (n = 17) </plain></SENT>
<SENT sid="2" pm="."><plain>Both groups received 1 mg.kg-1 of midazolam transrectally 30 min before the anesthesia induction and level of sedation was measured with six point scales </plain></SENT>
<SENT sid="3" pm="."><plain>Significantly lower level of sedation score was recognized in the group that showed hypoperfusion in bifrontal regions (P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Our finding may suggest that regional <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> may modify the sedative effect of midazolam in children with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e> </plain></SENT>
</text></document>